Cancer Research UK Cambridge Research Institute, Cambridge, UK.
Lancet Oncol. 2011 Nov;12(12):1169-74. doi: 10.1016/S1470-2045(11)70123-1.
High-grade serous ovarian cancers account for most ovarian-cancer mortality. Although this disease initially responds well to platinum-based chemotherapy, relapse and progression to chemotherapy resistance are frequently seen. Time to relapse after first-line therapy is a predictor of response to secondary platinum treatment: more than 12 months is associated with high chance of a secondary response, whereas relapses within 6 months generally indicate platinum resistance. In this Personal View we discuss whether patterns of response, relapse, and the development of drug resistance in high-grade serous ovarian cancers are related to distinct underlying molecular and cellular biological characteristics. In particular, we propose that rapid relapse with platinum-resistant disease is due to minor subpopulations of intrinsically resistant cancer cells at presentation.
高级别浆液性卵巢癌是导致大多数卵巢癌死亡的主要原因。尽管这种疾病最初对铂类化疗反应良好，但经常会出现复发和进展为化疗耐药。一线治疗后复发的时间是预测二线铂类治疗反应的指标：超过 12 个月与二次反应的高几率相关，而 6 个月内的复发通常表明铂类耐药。在本个人观点中，我们讨论了高级别浆液性卵巢癌的反应、复发和耐药发展模式是否与不同的潜在分子和细胞生物学特征相关。特别是，我们提出快速复发伴铂耐药疾病是由于初始时存在内在耐药的癌细胞亚群。
